What is it about?
The control of the glycemic level among diabetes/T2 patients is very important for their long term survival and avoiding further complexities including micro/macrovascular diseases as well as diabetic neuropathy. Vildagliptin (VD) is a drug that has addressed these issues successfully with the desired safety portfolio. We used DNA-nanocubes for initial nano-encapsulation of VD followed by HPMC/EC coating.
Featured Image
Read the Original
This page is a summary of: DNA scaffold nanoparticles coated with HPMC/EC for oral delivery, International Journal of Pharmaceutics, May 2019, Elsevier,
DOI: 10.1016/j.ijpharm.2019.03.054.
You can read the full text:
Contributors
The following have contributed to this page
